The long non-coding RNA EGOT promotes pancreatic cancer progression by sequestering miR-214 to derepress PLS3 expression

Jie Yao, Heng Duan, Zechang Xin, Peng Liu, Lijie Cai, Jinrui Han, Xiaodong Wang, Zhennan Li, Jianjun QianResearch Square 2022 · DOI

Abstract

Background: Long non-coding RNAs (lncRNAs) have been shown to play central roles in diverse oncogenic contexts. Database-based bioinformatics analyses indicated that pancreatic cancer (PC) samples exhibit the upregulation of the lncRNA EGOT. The present study was therefore designed to explore the role of this lncRNA in PC, focusing on its ability to regulate the EGOT/miR-214/PLS3 axis.

Methods: A qPCR approach was used to quantify EGOT, miR-214, and PLS3 mRNA levels in PC cells, while PLS3 protein levels were examined via Western blotting. Tumor cell invasivity and proliferation were measured through CCK-8, EdU, and wound healing assays. The impact of EGOR knockdown on in vivo PC tumor growth was additionally assessed.

Results: EGOT upregulation was observed in PC cells, and the knockdown of this lncRNA significantly impaired their migration, proliferation, and invasion. Direct binding interactions between miR-214 and both EGOT and PSL3 were detected, and miR-214 inhibition was sufficient to partially reverse the impact of EGOT knockdown on PLS3 expression and PC cell proliferative and migratory activity. Knocking down EGOT also suppressed the in vivo growth of PC tumors, and relationships between EGOT, miR-214, and PLS3 were confirmed in this animal model system.

Conclusion: We confirmed that EGOT serves as an important regulator of PC development, suggesting that it may be a valuable diagnostic biomarker and/or therapeutic target in this oncogenic context.

Introduction

Pancreatic cancer (PC) remains one of the most lethal malignancies worldwide, often referred to as the "king of cancer" due to its aggressive nature, late-stage diagnosis, and resistance to conventional therapies. With a five-year survival rate remaining below 10%, there is a critical need to identify the molecular drivers of its progression. While traditional research has focused on protein-coding genes, recent evidence highlights the role of long non-coding RNAs (lncRNAs)—transcripts longer than 200 nucleotides that regulate gene expression without being translated into proteins. This study investigates the lncRNA EGOT, which is overexpressed in PC, and its role in a specific signaling axis that promotes tumor growth and metastasis.

Methodology

The researchers utilized a multi-disciplinary approach to map the EGOT/miR-214/PLS3 pathway:

  • Expression Profiling: qPCR and Western blotting were used to measure RNA and protein levels across five PC cell lines (PANC-1, AsPC-1, HPAF-II, SW1990, and CFPAC-1) compared to normal HPDE cells.
  • Functional Assays: To determine the impact of EGOT, the gene was silenced using siRNA (knockdown). Proliferation was measured via CCK-8 and EdU assays, while migration and invasion were assessed through wound healing and Transwell assays.
  • Mechanistic Validation: Luciferase reporter assays and fluorescence in situ hybridization (FISH) were used to confirm physical binding between EGOT, miR-214, and PLS3.
  • In Vivo Models: Modified cancer cells were implanted into nude mice to observe the effects of EGOT knockdown on tumor volume and weight in a living system.

Results

EGOT Upregulation and Cellular Impact

Bioinformatics and experimental data confirmed that EGOT is significantly upregulated in pancreatic cancer cells. Functional testing showed that silencing EGOT drastically reduced the ability of these cells to multiply and spread.

Figure 1: Experimental evidence showing that knocking down EGOT significantly reduces the ability of pancreatic cancer cells to proliferate and migrate.

The Competitive Endogenous RNA (ceRNA) Mechanism

The study identified a "decoy" strategy employed by cancer cells. Normally, the microRNA miR-214 acts as a tumor suppressor by silencing the PLS3 gene. In pancreatic cancer, the overproduced EGOT acts as a molecular "sponge," sequestering miR-214. This prevents miR-214 from binding to PLS3, thereby "derepressing" the protein. High levels of PLS3, an actin-binding protein, then facilitate the structural changes necessary for cancer cell invasion and rapid division.

In Vivo Validation

In mouse xenograft models, tumors with silenced EGOT grew significantly slower and were smaller in both volume and weight compared to controls. Analysis of these tumors confirmed the inverse relationship between EGOT and miR-214, as well as the subsequent reduction in PLS3 levels, validating the entire axis in vivo.

Discussion and Conclusion

This research identifies EGOT as a potent oncogenic lncRNA in pancreatic cancer. By acting as a ceRNA for miR-214, EGOT drives the expression of PLS3, fueling tumor progression. While these findings offer a promising new target for therapy, further clinical validation using human primary tumor samples is required. Future work should also explore the potential for targeted delivery of EGOT-silencing molecules as a novel treatment strategy for this devastating disease.

Summary updated

Abstract

<title>Abstract</title> Background<bold>: </bold>Long non-coding RNAs (lncRNAs) have been shown to play central roles in diverse oncogenic contexts. Database-based bioinformatics analyses indicated that pancreatic cancer (PC) samples exhibit the upregulation of the lncRNA EGOT. The present study was therefore designed to explore the role of this lncRNA in PC, focusing on its ability to regulate the EGOT/miR-214/PLS3 axis.Methods<bold>: </bold>A qPCR approach was used to quantify EGOT, miR-214, and PLS3 mRNA levels in PC cells, while PLS3 protein levels were examined via Western blotting. Tumor cell invasivity and proliferation were measured through CCK-8, EdU, and wound healing assays. The impact of EGOR knockdown on in vivo<italic> </italic>PC tumor growth was additionally assessed. Results: EGOT upregulation was observed in PC cells, and the knockdown of this lncRNA significantly impaired their migration, proliferation, and invasion. Direct binding interactions between miR-214 and both EGOT and PSL3 were detected, and miR-214 inhibition was sufficient to partially reverse the impact of EGOT knockdown on PLS3 expression and PC cell proliferative and migratory activity. Knocking down EGOT also suppressed the in vivo<italic> </italic>growth of PC tumors, and relationships between EGOT, miR-214, and PLS3 were confirmed in this animal model system. Conclusion:We confirmed that EGOT serves as an important regulator of PC development, suggesting that it may be a valuable diagnostic biomarker and/or therapeutic target in this oncogenic context.
BibTeX
@inproceedings{yao2022long,
  author = {Jie Yao and Heng Duan and Zechang Xin and Peng Liu and Lijie Cai and Jinrui Han and Xiaodong Wang and Zhennan Li and Jianjun Qian},
  title = {{The long non-coding RNA EGOT promotes pancreatic cancer progression by sequestering miR-214 to derepress PLS3 expression}},
  booktitle = {Research Square},
  year = {2022},
  doi = {10.21203/rs.3.rs-1415870/v1},
}
Figure